Female sexual dysfunction treatment
US6193992A · kind A · utility
28Cited by
2References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 2, 1999 |
| Grant date | Feb 27, 2001 |
| Priority date | — |
| Expiry date | Jul 2, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P15/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Sexual dysfunction in human females can be ameliorated, without substantial undesirable side effects, by apomorphine. Administration of apomorphine increases nerve stimulated clitoral intracavernosal blood flow and vaginal wall blood flow for enhanced clitoral erection and vaginal engorgement in a female. A plasma concentration of apomorphine of no more than about 5.5 nanograms per milliliter is preferably maintained.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.